Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer,
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’
Quick Look: Perficient’s stock soared after an analyst upgrade and acquisition news, peaking at $73.70. Multiple analysts upgraded Perficient, with targets ranging from $59 to $77. EQT AB announced its acquisition of Perficient for $3 billion, offering $76 per
Quick Look: Snapchat achieved $1.2B in revenue, surpassing the expected $1.1B. Reported $0.03 per share against a forecasted loss of $0.05. Daily active users reached 422M, exceeding expectations. Snapchat has delivered outstanding financial results for the first quarter of
Quick Look: Hasbro reports a strong recovery with Q1 earnings of $58.2 million, a sharp contrast to last year’s loss. Despite a 24.3% drop in revenue to $757.3 million, performance surpassed analysts’ expectations. The Wizards of the Coast and
Friday was still markedly turbulent for world markets as economic news focused of the slide on Asian shares to 20-month lows. Meanwhile, S&P futures fell steeply and China’s yuan weakened. Anticipation for corporate profits also added to the lingering
Anxiety about China’s sluggish economy growth spill across Asian markets on Monday while US stock futures turning down and Chinese shares lingering in the red as concerns about US corporate earnings and global growth continued to pull down sentiment.
IBM Corp’s $34 billion deal to acquire Red Hat Inc. drove shares in the small but fast growing software maker 50 percent higher on Monday, reflecting the huge premium IBM is paying to ward off any potential challenger bids.
Asian stock markets and US equity futures posted decent gains on Monday over the hopes of a solid US holiday sales. Read more here!
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’ ratings from Citigroup and Stifel, and robust institutional support. Summit
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’ ratings from Citigroup and Stifel, and robust institutional support.
Quick Look: Perficient’s stock soared after an analyst upgrade and acquisition news, peaking at $73.70. Multiple analysts upgraded Perficient, with targets ranging from $59 to $77. EQT AB announced its acquisition of Perficient for $3 billion, offering $76 per share. Notable insider sales and strong institutional interest were
Quick Look: Snapchat achieved $1.2B in revenue, surpassing the expected $1.1B. Reported $0.03 per share against a forecasted loss of $0.05. Daily active users reached 422M, exceeding expectations. Snapchat has delivered outstanding financial results for the first quarter of 2024. The company outstripped analyst predictions on key financial
Quick Look: Hasbro reports a strong recovery with Q1 earnings of $58.2 million, a sharp contrast to last year’s loss. Despite a 24.3% drop in revenue to $757.3 million, performance surpassed analysts’ expectations. The Wizards of the Coast and Digital Gaming segment grew by 7%, led by games
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported